MediciNova, Inc.

NasdaqGM:MNOV 주식 리포트

시가총액: US$68.4m

MediciNova 향후 성장

Future 기준 점검 5/6

MediciNova은 연간 수입과 매출이 각각 67.9%와 73% 증가할 것으로 예상되고 EPS는 연간 68.3%만큼 증가할 것으로 예상됩니다.

핵심 정보

67.9%

이익 성장률

68.32%

EPS 성장률

Biotechs 이익 성장25.4%
매출 성장률73.0%
향후 자기자본이익률n/a
애널리스트 커버리지

Low

마지막 업데이트18 May 2026

최근 향후 성장 업데이트

Recent updates

분석 기사 • Aug 28

Companies Like MediciNova (NASDAQ:MNOV) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
분석 기사 • Apr 19

We're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
분석 기사 • Nov 27

MediciNova (NASDAQ:MNOV) Is In A Good Position To Deliver On Growth Plans

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
분석 기사 • Jul 11

We're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
분석 기사 • Mar 18

Here's Why We're Not Too Worried About MediciNova's (NASDAQ:MNOV) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
분석 기사 • Oct 12

We Think MediciNova (NASDAQ:MNOV) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Sep 15

MediciNova to get US patent for MN-166 to treat brain cancer

MediciNova (NASDAQ:MNOV) said it will receive a new patent from the U.S. Patent and Trademark Office which covers MN-166 (ibudilast) to treat glioblastoma. The new patent is expected to expire no earlier than February 2039, the company said in a Sept. 14 press release. Glioblastoma is a type of cancer that can occur in the brain or spinal cord. The allowed claims cover a method of treating a patient with glioblastoma or recurrent glioblastoma wherein a patient expresses unmethylated MGMT, using MN-166 (ibudilast) in combination with one or more other therapeutic agents. "Results of our glioblastoma animal model study showed that median survival was longer in the group that received combination treatment with MN-166 plus temozolomide compared to the group that received the standard treatment of temozolomide alone," said MediciNova Chief Medical Officer Kazuko Matsuda.
Seeking Alpha • Aug 16

MediciNova's MN-166 to be part of study to treat Long COVID

MediciNova (NASDAQ:MNOV) said it plans to participate in a grant-funded clinical trial, dubbed RECLAIM, to evaluate MN-166 (ibudilast) and other therapies for treating Long COVID. The company added that it reached an agreement to collaborate with the University Health Network.
Seeking Alpha • Jul 22

MediciNova begins study of parenteral formulation of MN-166

MediciNova (NASDAQ:MNOV) said it started a first-in-human study of a new parenteral formulation of MN-166 (ibudilast). The company said the newly developed MN-166 (ibudilast) formulation will provide an additional option besides the current oral formulation. "With MN-166 expected to be effective to treat a variety of diseases, we believe expanding to a parenteral formulation increases the feasibility of treating more target indications, thus increasing the value of MN-166," said MediciNova Chief Medical Officer Kazuko Matsuda. In April, the company reported data from a phase 2 trial of MN-166 for alcohol use disorder, showing that the drug reduced alcohol craving on non-drinking days.
Seeking Alpha • Jun 30

MediciNova announces extension of BARDA contract for Ibudilast development

MediciNova (NASDAQ:MNOV) said on Wednesday that a modification to its contract with the Biomedical Advanced Research and Development Authority (BARDA) for its small molecule candidate MN-166 (ibudilast). Under the partnership with BARDA, the company will repurpose MN-166 as a potential medical countermeasure against chlorine gas-induced lung damage such as acute respiratory distress syndrome (ARDS) and acute lung injury (ALI). The contract was amended to extend the period of performance until March 2023. BARDA, a division of the U.S. Department of Health and Human Services will fund the proof-of-concept studies in preclinical models of chlorine gas-induced acute lung injury. The project has been funded in whole or in part with federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority. Last year in March, MediciNova jumps on BARDA partnership for Ibudilast development. Shares are up 2.75% after-hours.
분석 기사 • Mar 19

We're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
분석 기사 • Nov 23

MediciNova (NASDAQ:MNOV) Is In A Strong Position To Grow Its Business

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Aug 31

MediciNova: The Pain Of A Positive Outlook

MediciNova reported blasé Q2 2021 earnings on 08/12/2021. MediciNova's core pipeline consists of two candidate therapies being developed in treatment of eleven indications. MediciNova's MS program is a high potential, late stage program which has been in stall mode. MediciNova has operated under less financial strain than expected for a company with its advanced pipeline.
Seeking Alpha • Jun 21

MediciNova stock climbs 31% on positive MN-166 data in mid-stage alcohol use disorder study

MediciNova (MNOV) soars 30.6% premarket after announcing positive results from a Phase 2 trial of MN-166 (ibudilast) in alcohol use disorder ((AUD)), published in Nature’s Translational Psychiatry. The Phase 2 trial evaluated the effect of 14 days of ibudilast treatment on mood, heavy drinking, and neural reward signals in individuals with AUD. A total of 52 patients were enrolled. Key results include: Ibudilast did not have a significant effect on negative mood.Ibudilast, relative to placebo, reduced the odds of heavy drinking across time
분석 기사 • May 15

Companies Like MediciNova (NASDAQ:MNOV) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

이익 및 매출 성장 예측

NasdaqGM:MNOV - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)
날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수
12/31/202828-9-38N/A3
12/31/20270-26-34N/A3
12/31/20260-14-30N/A2
3/31/20261-12-10-9N/A
12/31/20250-12-10-10N/A
9/30/20250-12-10-10N/A
6/30/20250-12-10-10N/A
3/31/2025N/A-11-11-11N/A
12/31/2024N/A-11-11-11N/A
9/30/2024N/A-10-9-9N/A
6/30/20241-8-9-9N/A
3/31/20241-8-8-8N/A
12/31/20231-9-7-7N/A
9/30/20231-10-11-11N/A
6/30/2023N/A-12-12-12N/A
3/31/2023N/A-14-12-12N/A
12/31/2022N/A-14-13-13N/A
9/30/2022N/A-13-13-13N/A
6/30/20220-13-13-13N/A
3/31/20220-13-9-9N/A
12/31/20214-10-9-9N/A
9/30/20214-11-8-8N/A
6/30/20214-11-9-9N/A
3/31/20214-11-12-12N/A
12/31/2020N/A-14-11-11N/A
9/30/2020N/A-13-11-11N/A
6/30/2020N/A-12-9-9N/A
3/31/2020N/A-11-9-9N/A
12/31/2019N/A-13N/A-9N/A
9/30/2019N/A-11N/A-8N/A
6/30/2019N/A-16N/A-8N/A
3/31/2019N/A-15N/A-8N/A
12/31/2018N/A-15N/A-9N/A
9/30/2018N/A-16N/A-9N/A
6/30/2018N/A-13N/A-9N/A
3/31/2018N/A-13N/A-8N/A
12/31/2017N/A-11N/A-7N/A
9/30/2017N/A-11N/A-7N/A
6/30/2017N/A-10N/A-7N/A
3/31/2017N/A-11N/A-7N/A
12/31/2016N/A-11N/A-7N/A
9/30/2016N/A-12N/A-7N/A
6/30/2016N/A-11N/A-7N/A
3/31/2016N/A-10N/A-6N/A
12/31/2015N/A-9N/A-7N/A
9/30/2015N/A-8N/A-7N/A

애널리스트 향후 성장 전망

수입 대 저축률: MNOV 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률(3.5%)보다 빠른 성장으로 간주됩니다.

수익 vs 시장: MNOV (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.

고성장 수익: MNOV 향후 3년 내에 수익을 낼 것으로 예상됩니다.

수익 대 시장: MNOV 의 수익(연간 73%)이 US 시장(연간 11.7%)보다 빠르게 성장할 것으로 예상됩니다.

고성장 매출: MNOV 의 수익(연간 73%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: MNOV의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.

성장 기업 찾아보기

7D

1Y

7D

1Y

7D

1Y

기업 분석 및 재무 데이터 상태

데이터최종 업데이트 (UTC 시간)
기업 분석2026/05/21 11:13
종가2026/05/21 00:00
수익2026/03/31
연간 수익2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지데이터기간미국 소스 예시 *
기업 재무제표10년
  • 손익계산서
  • 현금흐름표
  • 대차대조표
분석가 컨센서스 추정치+3년
  • 재무 예측
  • 분석가 목표주가
시장 가격30년
  • 주가
  • 배당, 분할 및 기타 조치
지분 구조10년
  • 주요 주주
  • 내부자 거래
경영진10년
  • 리더십 팀
  • 이사회
주요 개발10년
  • 회사 공시

* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

MediciNova, Inc.는 8명의 분석가가 다루고 있습니다. 이 중 3명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가기관
Jason KolbertD. Boral Capital LLC.
Lander Egaña-GorroñoH.C. Wainwright & Co.
Elemer PirosLucid Capital Markets